1 |
MacNeil JR, Su JR, Broder KR, et al. Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients-United States, April 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7017e4.htm as of 2021. 4. 30.
|
2 |
Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020. 586: 589-593.
DOI
|
3 |
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021a. 397: 99-111.
DOI
|
4 |
Wadman M. Novavax launches pivotal U.S. trial of dark horse COVID-19 vaccine after manufacturing delays. https://www.science.org/content/article/novavax-launches-pivotal-us-trial-dark-horse-covid-19-vaccine-after-manufacturing as of 2020a. 12. 28.
|
5 |
Wadman M. The long shot. Science. 2020b. 370: 649-653.
DOI
|
6 |
Walls AC, Park YJ, Tortorici MA et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020. 181: 281-292; e6.
DOI
|
7 |
Anderson M, Stec M, Rewane A, et al. SARS-CoV-2 antibody responses in infection-naive or previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine. JAMA Netw Open. 2021. 4: e2119741.
DOI
|
8 |
Businesswire.com. Moderna announces primary efficacy analysis in phase 3 COVE study for Its COVID-19 vaccine candidate and filing today with U.S. FDA for emergency use authorization. https://www.businesswire.com/news/home/20201130005506/en/Moderna-Announces-Primary-Efficacy-Analysis-in-Phase-3-COVE-Study-for-Its-COVID-19-Vaccine-Candidate-and-Filing-Today-with-U.S.-FDA-for-Emergency-Use-Authorization as of 2020. 11. 30.
|
9 |
Ministry of Food and Drug Safety of Korea. Press release in Ministry of Food and Drug Safety of Korea. file:///C:/Users/ajoumg/Downloads/1.12+%EB%B0%94%EC%9D%B4%EC%98%A4%EC%9D%98%EC%95%BD%ED%92%88%EC%A0%95%EC%B1%85%EA%B3%BC+%EB%93%B1.pdf as of 2022. 1. 12.
|
10 |
Kesselheim AS, Darrow JJ, Kulldorff M, et al. An overview of vaccine development, approval, and regulation, with implications for COVID-19. Health Aff. 2021. 40: 25-32.
DOI
|
11 |
Pfizer. Pfizer and BioNTech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccineas of 2020. 11. 18.
|
12 |
Centers for Disease Control and Prevention (CDC). Pfizer-BioNTech COVID-19 vaccine (also known as Comirnaty) overview and safety. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html as of 2022. 5. 20. -48
|
13 |
Centers for Disease Control and Prevention (CDC). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine-United States, December2020. 14-23. https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm?s_cid=mm7002e1_w as of 2021b. 1. 6.
|
14 |
Widge AT, Rouphael NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021. 384: 80-82.
DOI
|
15 |
Nunneley CE. COVID-19 vaccine candidates: 6 front-runners. https://abcnews.go.com/Health/covid-19-vaccine-candidates-front-runners/story?id=69881230 as of 2020. 4. 1.
|
16 |
Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. Jama. 2022. 327: 331-340.
DOI
|
17 |
Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021. 384: 1412-1423.
DOI
|
18 |
Walsh EE, Frenck RW Jr., Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020. 383: 2439-2450.
DOI
|
19 |
Choi DO, Lee KM. Development of COVID-19 neutralizing anti-body (NAb) detection kits using the S1 RBD protein of SARSCoV-2. Korean J Clin Lab Sci. 2021. 53: 257-265.
DOI
|
20 |
Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano. 2020. 14: 12522-12537.
DOI
|
21 |
Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021. 371: eabf4063.
DOI
|
22 |
Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021. 384: 2259-2261.
DOI
|
23 |
Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021. 384: 1899-1909.
DOI
|
24 |
Piano Mortari E, Russo C, Vinci MR, et al. Highly specific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA. Cells. 2021. 10: 2541.
DOI
|
25 |
Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021. 396: 1979-1993.
|
26 |
Shay DK, Gee J, Su JR, et al. Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine - United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021. 70: 680-684.
DOI
|
27 |
Song GS, Lee YR, Kim SM, et al. Laboratory diagnosis of coronavirus disease 19 (COVID-19) in Korea: Current status, limitation, and challenges. Korean J Clin Lab Sci. 2020. 52: 284-295.
DOI
|
28 |
World Health Organization (WHO). Weekly epidemiological update on COVID-19-20 April 2022. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---20-april-2022 as of 2022. 4. 20.
|
29 |
Salzman S. Johnson & Johnson single-shot vaccine 85% effective against severe COVID-19 disease. https://web.archive.org/web/20210201092739/https://abcnews.go.com/Health/johnson-johnson-single-shot-vaccine-85-effective-severe/story?id=75557358 as of 2021. 1. 29.
|
30 |
Team CC-R, U.S. Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020- January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021. 70: 125-129.
DOI
|
31 |
Teijaro JR, Farber DL. COVID-19 vaccines: Modes of immune activation and future challenges. Nat Rev Immunol. 2021. 21: 195-197.
DOI
|
32 |
U.S. Food and Drug Administration. FDA Briefing document Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. https://www.fda.gov/media/146217/download as of 2021a. 2. 26.
|
33 |
Anderson RD, Haskell RE, Xia H, Roessler BJ, Davidson BL. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther. 2000. 7: 1034-1038.
DOI
|
34 |
Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet. 2021b. 397: 881-891.
DOI
|
35 |
The Guardian. Fully vaccinated people account for 1.2% of England's Covid-19 deaths. https://www.theguardian.com/world/2021/sep/13/fully-vaccinated-people-account-for-12-of-englands-covid-19-deaths as of 2021b. 9. 13.
|
36 |
Tregoning JS, Brown ES, Cheeseman HM, et al. Vaccines for COVID-19. Clin Exp Immunol. 2020. 202: 162-192.
DOI
|
37 |
Turonova B, Sikora M, Schurmann C, et al. In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. Science. 2020. 370: 203-208.
DOI
|
38 |
U.S. Food and Drug Administration. FDA issues emergency use authorization for third COVID-19 vaccine. https://web.archive.org/web/20210318174827/https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine as of 2021b. 2. 27.
|
39 |
U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals. https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals as of 2022. 5. 5.
|
40 |
van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020. 586: 578-582.
DOI
|
41 |
Gaebler C, Nussenzweig MC. All eyes on a hurdle race for a SARS-CoV-2 vaccine. Nature. 2020. 586: 501-502.
DOI
|
42 |
Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020b. 27: 325-328. -11
DOI
|
43 |
National Health Service (NHS). Coronavirus vaccine. https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/ as of 2022. 5. 12.
|
44 |
Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: Antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. medRxiv. 2020. 20065771.
|
45 |
Novavax. Novavax publishes results of United Kingdom phase 3 clinical trial in New England Journal of Medicine, demonstrating high levels of efficacy of COVID-19 vaccine. https://ir.novavax.com/2021-06-30-Novavax-Publishes-Results-of-United-Kingdom-Phase-3-Clinical-Trial-in-New-England-Journal-of-Medicine,-Demonstrating-High-Levels-of-Efficacy-of-COVID-19-Vaccine?sf146717139=1 as of 2021. 6. 30.
|
46 |
European Medicines Agency (EMA). Comirnaty. https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty as of 2022a. 3. 12.
|
47 |
European Medicines Agency (EMA). Nuvaxovid. https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid as of 2021b. 12. 23.
|
48 |
Frederiksen LSF, Zhang Y, Foged C, Thakur A. The long road toward COVID-19 herd immunity: Vaccine platform technologies and mass immunization strategies. Front Immunol. 2020. 11: 1817.
DOI
|
49 |
Greenwood B. The contribution of vaccination to global health: Past, present and future. Philos Trans R Soc Lond B Biol Sci. 2014. 369: 20130433.
DOI
|
50 |
Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021. 384: 2092-2101.
DOI
|
51 |
Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021. 385: 1172-1183.
DOI
|
52 |
Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021. 384: 2254-2256.
DOI
|
53 |
European Medicines Agency (EMA). Spikevax (previously COVID19 Vaccine Moderna). https://www.ema.europa.eu/en/medicines /human/EPAR/spikevax as of 2022b. 5. 12
|
54 |
Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020. 11: 585354.
DOI
|
55 |
Centers for Disease Control and Prevention (CDC). The possibility of COVID-19 after vaccination: Breakthrough infections. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html#anchor_1636141727968 as of 2021c. 12. 17.
|
56 |
Centers for Disease Control and Prevention (CDC). Johnson & Johnson's Janssen COVID-19 Vaccine Information. https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html as of 2021a. 3. 29.
|
57 |
Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022. 386: 531-543.
DOI
|
58 |
World Health Organization (WHO). Background document to the WHO interim recommendations for use of the mRNA-1273 vaccine (Moderna), 3 February 2021. http://apps.who.int/iris/handle/10665/339218 as of 2021. 2. 3.
|
59 |
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020a. 579: 265-269. -8
DOI
|
60 |
Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019. 10: 594.
DOI
|
61 |
European Medicines Agency (EMA). Vaxzevria: EMA advises against use in people with history of capillary leak syndrome. https://www.ema.europa.eu/en/news/vaxzevria-ema-advises-against-use-people-history-capillary-leak-syndrome as of 2021a. 6. 11.
|
62 |
Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020. 396: 467-478.
DOI
|
63 |
Goel RR, Apostolidis SA, Painter MM, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci Immunol. 2021. 6: eabi6950.
DOI
|
64 |
Guo L, Wang G, Wang Y, et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: A longitudinal cohort study. Lancet Microbe. 2022. 3: e348-e356.
DOI
|
65 |
Hotez PJ, Bottazzi ME. Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. Annu Rev Med. 2022. 73: 55-64.
DOI
|
66 |
Howard J. FDA grants full approval to Pfizer/BioNTech Covid-19 vaccine, opening door to more vaccine mandates. https://edition.cnn.com/2021/08/23/health/fda-approval-pfizer-covid-vaccine/index.html as of 2021. 8. 23.
|
67 |
Jenco J. Moderna testing COVID-19 vaccine in children under 12. https://publications.aap.org/aapnews/news/12031 as of 2021.
|
68 |
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020. 579: 270-273
DOI
|
69 |
The Guardian. Spain, Belgium and Italy restrict AstraZeneca Covid vaccine to older people. https://www.theguardian.com/society/2021/apr/08/spain-belgium-and-italy-restrict-astrazeneca-covid-vaccine-to-older-people as of 2021a. 4. 8.
|
70 |
Vogel G, Frankel JC. Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. https://www.science.org/content/article/israel-reports-link-between-rare-cases-heart-inflammation-and-covid-19-vaccination as of 2021. 6. 1.
|
71 |
Kandeil A, Mostafa A, Hegazy RR, et al. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine: Preclinical studies. Vaccines (Basel). 2021. 9: 214.
DOI
|
72 |
Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020. 383: 2320-2332.
DOI
|
73 |
Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2-Preliminary report. N Engl J Med. 2020. 383: 1920-1931.
DOI
|
74 |
Department of Health and Social Care. One year anniversary of UK deploying Oxford-AstraZeneca vaccine. https://www.gov.uk/government/news/one-year-anniversary-of-uk-deploying-oxford-astrazeneca-vaccine as of 2022. 1. 4.
|
75 |
James G, Nick T. Covid-19: Oxford-AstraZeneca coronavirus vaccine approved for use in UK. https://www.bbc.com/news/health-55280671 as of 2020. 12. 30.
|
76 |
Kim EJ, Lee DS. Coronaviruses: SARS, MERS and COVID-19. Korean J Clin Lab Sci. 2020b. 52: 297-309.
DOI
|
77 |
Korea Disease Control and Prevention Agency. http://ncov.mohw.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=6531&board_id=312&contSeq=6531 as of 2022c. 3. 31.
|
78 |
Korea Disease Control and Prevention Agency. http://ncov.mohw.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=6569&contSeq=6569&board_id=312&gubun=ALL as of 2022b. 4. 14.
|
79 |
Kim MW. A review of recent trend of COVID-19 infection and correlation with pulmonary function. Biomed Sci Lett. 2020a. 26: 127-135.
DOI
|
80 |
Korea Disease Control and Prevention Agency, Cases of COVID-19 in Korea 2022a. http://ncov.mohw.go.kr/bdBoardList_Real.do
|
81 |
Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020. 584: 457-462.
DOI
|
82 |
Leo L. Hope to launch Covovax by September, says Serum Institute CEO. https://www.livemint.com/companies/news/hope-to-launch-covovax-by-september-says-serum-institute-ceo-11616834205232.html as of 2021. 5. 27.
|
83 |
Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci. 2021. 25: 1663-1669.
|